QUADRAMET

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug QUADRAMET contains one active pharmaceutical ingredient (API):

1	Samarium ¹⁵³Sm lexidronam UNII 745X144DZY - SAMARIUM SM-153 LEXIDRONAM
	Samarium has an affinity for skeletal tissue and concentrates in areas of bone turnover in intimate association with hydroxyapatite. It is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium (99mTc)-labelled biphosphonates on bone scan.
	Read more about Samarium ¹⁵³Sm lexidronam

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
QUADRAMET Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V10BX02	Samarium (153Sm) lexidronam	V Various → V10 Therapeutic radiopharmaceuticals → V10B Pain palliation (bone seeking agents) → V10BX Various pain palliation radiopharmaceuticals
Discover more medicines within V10BX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1197301
ES	Centro de información online de medicamentos de la AEMPS	98057001
FR	Base de données publique des médicaments	68052014
GB	Medicines & Healthcare Products Regulatory Agency	394528, 394587, 394593, 394596, 394600, 394607, 394610, 394613, 394635, 394639, 394644, 394647, 394652, 394656, 394660, 394667, 394671, 394675, 394679, 394683, 394687
IT	Agenzia del Farmaco	033111016
LT	Valstybinė vaistų kontrolės tarnyba	1030554
PL	Rejestru Produktów Leczniczych	100110300
US	FDA, National Drug Code	11994-016